Uterus Transplantation to Treat Infertility

Description

This research study will use uterus transplantation to treat uterine factor infertility, also known as the inability to bear children due to not having a uterus. The purpose of this study is to enable women seeking genetically-related children and the childbearing experience to experience pregnancy and birth a child. In this study, living donors will undergo surgery to give the donor's uterus to another woman. The woman who receives the transplant will take immunosuppression to keep the uterus and herself healthy. Because taking immunosuppressive medicine has side effects, uterus transplantation is intended to be temporary, lasting about 5 years. The goals of the study are successful pregnancy and the birth of one, and possibly two, healthy babies per transplant patient. The uterus is to be removed and immunosuppression stopped following the birth of a child. Offspring are delivered by Caesarian section, at which time the transplant may also be removed. Transplant candidates must have fertilized, frozen (cryopreserved) embryos at a Johns Hopkins facility before undergoing transplantation. Transplant candidates will be asked to identify candidates' potential uterus donor. Altruistic donors, or women who want to donate without knowing a potential recipient, may also participate. All potential donors will be screened to see if the donors are a good match for a recipient and are healthy enough to have the donation surgery. Study Duration: * Uterus Donors: Screening through about 12 months following the transplant operation. * Uterus Recipients: Recipients may have the uterus for about 5 years. After the transplant is removed, the study team will ask for yearly follow-ups for another 5 years. * Children born from transplanted uteruses: The study team asks to follow offspring yearly through age 21 years.

Conditions

Uterine Factor Infertility

Talk to us

Study Overview

On this page

Study Details

Study overview

This research study will use uterus transplantation to treat uterine factor infertility, also known as the inability to bear children due to not having a uterus. The purpose of this study is to enable women seeking genetically-related children and the childbearing experience to experience pregnancy and birth a child. In this study, living donors will undergo surgery to give the donor's uterus to another woman. The woman who receives the transplant will take immunosuppression to keep the uterus and herself healthy. Because taking immunosuppressive medicine has side effects, uterus transplantation is intended to be temporary, lasting about 5 years. The goals of the study are successful pregnancy and the birth of one, and possibly two, healthy babies per transplant patient. The uterus is to be removed and immunosuppression stopped following the birth of a child. Offspring are delivered by Caesarian section, at which time the transplant may also be removed. Transplant candidates must have fertilized, frozen (cryopreserved) embryos at a Johns Hopkins facility before undergoing transplantation. Transplant candidates will be asked to identify candidates' potential uterus donor. Altruistic donors, or women who want to donate without knowing a potential recipient, may also participate. All potential donors will be screened to see if the donors are a good match for a recipient and are healthy enough to have the donation surgery. Study Duration: * Uterus Donors: Screening through about 12 months following the transplant operation. * Uterus Recipients: Recipients may have the uterus for about 5 years. After the transplant is removed, the study team will ask for yearly follow-ups for another 5 years. * Children born from transplanted uteruses: The study team asks to follow offspring yearly through age 21 years.

OPRTUNTI: Offering Potential for Reproduction Through Transplantation of Uterus iN the Treatment of Infertility

Uterus Transplantation to Treat Infertility

Condition
Uterine Factor Infertility
Intervention / Treatment

-

Contacts and Locations

Baltimore

Johns Hopkins University School of Medicine, Baltimore, Maryland, United States, 21287

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Genotypic female of any race, color, or ethnicity.
  • * Uterine factor infertility.
  • * Aged 18-38 years at time of egg retrieval.
  • * Strong desire to undergo uterus transplant in order to become pregnant and give birth to a child.
  • * Embryo cryopreservation with embryos located at Johns Hopkins:
  • * Has a minimum of 4-8 cryopreserved normal embryos following Preimplantation Genetic Screening (PGS-screening).
  • * Willingness to undergo embryo implantation after uterus transplantation to achieve pregnancy.
  • * In the opinion of the study team, makes a reasonable effort to identify and refer her own potential uterus donor to the study team.
  • * Completes the protocol informed consent form.
  • * Non-smoker, defined by having never smoked or having quit \>6 consecutive months prior to screening.
  • * No co-existing medical condition which, in the opinion of the study team, could affect the immunosuppression protocol, surgical procedure, or ability to be pregnant or bear a child. (See Donor and Recipient Exclusion Criteria below. If the condition is amenable to treatment, the study team must agree that said condition should not significantly enhance the surgical risks of uterus transplantation.)
  • * Negative serum pregnancy test.
  • * Blood type compatible with donor.
  • * Negative crossmatch with donor.
  • * Patient agrees to comply with the protocol and states a dedication to the treatment regime.
  • * Agrees to uterus explanation following birth of a child and or 5 years without successful pregnancy.
  • * Positive for any of the following conditions:
  • * Insulin-dependent diabetes mellitus.
  • * Untreated sepsis.
  • * HIV (active or seropositive).
  • * Active tuberculosis.
  • * Active Hepatitis B infection.
  • * Active Hepatitis C infection.
  • * Viral encephalitis.
  • * Toxoplasmosis.
  • * Current/recent (within 3 months of donation/screening consent) IV drug abuse.
  • * Significant cardiac disease
  • * Significant vascular disease o
  • * Sensitized recipients with high levels (50%) of panel-reactive Human Leukocyte Antigens (HLA) antibodies.
  • * Conditions that may impact the success of the surgical procedure or increase the risk of postoperative complications including inherited coagulopathies like Hemophilia, Von-Willebrand's disease, Protein C and S deficiency, Thrombocythemias, Thalassemias, Sickle Cell disease, etc.
  • * Mixed connective tissue diseases and collagen diseases that can result in poor wound healing after surgery.
  • * Severe neurologic deficits.
  • * Patients considered unsuitable per the consulted Psychiatric/Psychologic appraisal.
  • * A history of medical non-compliance.

Ages Eligible for Study

18 Years to 38 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Johns Hopkins University,

Richard J Redett, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

2043-02-28